scholarly journals Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 nCoV ‐19 Corona Virus Vaccine (Recombinant)

2021 ◽  
Author(s):  
Sunmeet Sandhu ◽  
Anuj Bhatnagar ◽  
Harish Kumar ◽  
Prashant Kumar Dixit ◽  
Gourang Paliwal ◽  
...  
Keyword(s):  
Virus Vaccine ◽  
Leukocytoclastic Vasculitis ◽  
Cutaneous Manifestation ◽  
Vaccine Recombinant ◽  
Corona Virus

scholarly journals A prospective observational safety study on ChAdOx1 nCoV- 19 corona virus vaccine (recombinant) use in healthcare workers- first results from India

2021 ◽  
Author(s):  
Upinder Kaur ◽  
Bisweswar Ojha ◽  
Bhairav Kumar Pathak ◽  
Anup Singh ◽  
Kiran R Giri ◽  
...  
Keyword(s):  
Virus Vaccine ◽  
Healthcare Workers ◽  
Safety Data ◽  
Vaccine Recombinant ◽  
Safety Study ◽  
Northern India ◽  
Corona Virus ◽  
First Results ◽  
Grade 3 ◽  
The Uk

Vaccines are an important public health measure for tiding over the COVID-19 pandemic. Several vaccines have been approved in different countries for emergency use. In India, two vaccines have been currently approved- COVISHIELD (Serum Institute of India (SII)) which is a recombinant simian adenovirus-based vaccine and COVAXIN (Bharat Biotech) which is an inactivated SARS-CoV-2 vaccine. Our current study provides the first post approval safety data on ChAdOx1 nCoV- 19 corona virus vaccine (recombinant) use in healthcare workers in northern India (n=804). Around one half of vaccinees developed adverse events at any time post vaccination with majority of reactions being mild to moderate in severity. AEFIs were seen in 40% participants after first dose and around 16% participants after second dose. This observed reactogenicity is much less compared to 60-88% reactogenicity rate observed with Oxford-AstraZenecas ChAdOx1 vaccine in the UK based population. Individually, fever, injection site pain and headache were the commonly observed AEFIs. Overall, the frequency of systemic events of severity grade 3 was only 0.5% and is much less than the reported rates for other recombinant adenoviral vaccines. The rate of serious AEFIs in our study was only 0.1% (n=1). There was a possibility of this AEFI being an immunization stress related response. No deaths were reported in the vaccinees in our study during the study period. Reactogenicity rate was observed to decrease with age and was higher in females. On the basis of interim findings of this safety study, it may be interpreted that the ChAdOx1 nCoV-19 corona virus vaccine (recombinant) (COVISHIELD, Serum Institute of India) carries a good safety profile overall.

scholarly journals A Real World Evaluation of the safety and immunogenicity of the Covishield vaccine, ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant) in Health Care Workers (HCW) in National Capital Region (NCR) of India: A preliminary report

2021 ◽  
Author(s):  
Sushia Kataria ◽  
Pooja Sharma ◽  
Vikas Deswal ◽  
Kuldeep Kumar ◽  
Manish Kumar Singh ◽  
...  
Keyword(s):  
Health Care ◽  
Adverse Events ◽  
Virus Vaccine ◽  
Health Care Workers ◽  
Real World ◽  
Vaccine Recombinant ◽  
Serious Adverse Events ◽  
Corona Virus ◽  
Care Workers ◽  
History Of

Background: The SARS-CoV-2 pandemic has severely impacted health systems, economic and social progress globally in 2020. The rollout of vaccines in several parts of the world is being hailed as a solution to the crisis. With newer and more virulent serotypes on the horizon and limited vaccine available, evaluation of safety and immunogenicity is critical for rationalization of vaccine use in public health. Objective To evaluate real world safety, and, immunogenicity of the Covishield vaccine, ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant) in Health Care Workers (HCW) during the national vaccine roll out in the NCR, New Delhi. The safety is evaluated through Adverse Events and Serious Adverse Events reported though enhanced pharmacovigilance protocols, and, the immunogenicity by quantitative determination of anti-S1 and anti-S2 specific IgG antibodies to SARS-CoV-2 in serum samples collected before the receipt of the vaccine and 14 days after dose 1, using the fully automated LIAISON SARS-CoV-2 S1/S2 IgG test using the chemiluminescence immunoassay (CLIA) Results: In the two weeks after immunization with the Covishield vaccine {ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant)}, none of the 1638 evaluated participants reported any serious adverse events (ie require hospitalization or emergency room visit). Solicited adverse events reported via daily diary cards included pain (62.7%) and soreness (24.1%) at injection site as most common, whereas fever (48.4%), headache (43.4%), myalgia (38.4%), fatigue (33.4%), joint pain (27.0%) and nausea (16.0%) were most common solicited systemic adverse events on day 1. Majority of local and systemic adverse events were seen in first 2 days post vaccination and thereafter they resolved. Lesser reactogenicity was observed in subjects with age >50 years. No major difference was observed in adverse events when subjects were stratified based on history of COVID 19 disease or baseline seropositivity. In our study serostatus improved from 48.2% positive at baseline to 79.0% positive 2 weeks following first dose of vaccination. After first dose of vaccination overall higher percentage (98.2%) of seropositivity rates were observed in those with past history of COVID 19 disease Conclusion: The Covishield vaccine {ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant)}, was safe and reported mild self limiting adverse events over 2-4 days and had an good early (within 2 weeks) seroresponse .This holds the promise of far reaching impact on vaccine availability for a larger population and thereby providing a widespread coverage.

Acute Cardiac Events After ChAdOx1 nCoV-19 Corona Virus Vaccine

2022 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Rohit Singh ◽  
Sankha Shubhra Chakrabarti ◽  
Indrajeet Singh Gambhir ◽  
Ashish Verma ◽  
Ishan Kumar ◽  
...  
Keyword(s):  
Virus Vaccine ◽  
Cardiac Events ◽  
Corona Virus
Sign in / Sign up

Export Citation Format

Share Document